ArticleScientific reports2025
Association of hearing loss with cardiovascular and mortality risk in the general population.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Global trends and hotspots in diabetes and hearing loss: a 20-year systematic bibliometric study.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hearing loss affects over 1.5 billion individuals worldwide and is associated with significant challenges, including social isolation and cognitive decline. Emerging evidence suggests a link between hearing loss and cardiovascular diseases. Comprehensive epidemiological studies exploring these associations remain limited. Using data from the Gutenberg Health Study, a population-based cohort of 15,010 participants aged 35-74 years at baseline, we investigated the relationship between hearing loss, cardiovascular diseases and risk factors, and all-cause mortality. Participants underwent extensive audiometric assessments and clinical evaluations. Logistic regression and Cox proportional hazards models were applied to determine associations between hearing loss, cardiovascular health, and mortality, adjusting for potential confounders. Among the 8886 participants with complete hearing data, 35.1% exhibited some degree of hearing loss. Crude models revealed significant associations between hearing loss and various cardiovascular diseases and risk factors. However, these associations lost significance after adjustments for confounders, except for diabetes (adjusted odds ratio 1.24, 95% confidence interval (CI) 1.01-1.51). Hearing loss coincided with higher mortality in unadjusted analyses (hazard ratio 5.64, 95% CI 4.24-7.49), but this relationship disappeared after full adjustment. Hearing loss may serve as an early marker of systemic vascular dysfunction, particularly in diabetes, rather than an independent predictor of cardiovascular disease or mortality. It needs to be determined whether incorporating auditory health into broader cardiovascular assessments could improve early detection and prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.